New diagnostic and therapeutic radiopharmaceuticals using radiolabeled peptides develoopted by the genetic engineering.

本研究旨在利用放射性标记多肽开发新的诊断和治疗放射性药物，利用基因工程技术分析与白细胞反应的小鼠单抗并将其人源化用于临床，以降低鼠型抗体的免疫原性。经我所伦理委员会批准，~(99m)Tm标记的人源化抗体安全地应用于各种疾病患者。99mTc标记的人源化抗体定位于正常骨髓和化生骨为针状区。与原有的鼠源抗体相比，抗鼠抗体在患者血清中的产生是不存在的，99mTc标记的人源化抗体将是一种很有前途的检测骨转移和感染区域的试剂。然而，放射性核素标记的多肽很容易聚集，还有待研究。

This research project was performed to develop new diagnostic and therapeutic radiopharmaceuticals using radiolabeled peptides.By employing the genetic engineering, murine monoclonal antibodies reactive with white blood cells were analyzed and humanized for clinical use, in order to decrease the immunogenecity of murine type antibody. Technetium-99m labeled humanized antibodies were safely administered to patients with various diseases after getting the permission of ethical committee of our institute. 99mTc-labeled humanized antibodies localized in the normal bone marrow and metastic bones were demonstrated as acold area. Comparing to the original murine antibodies the production of anti-murine antidoby in patients' serum were neglible and 99mTc-labeled humanized antibodies will be a promising reagent for the detection of bone metastasis and also for the infectious regions. However, peptides radiolabeled with radionuclides were easily aggregated and remains to be investigated.